The starting point of Fumihisa Kojima’s business activities was web production and web marketing.

At Studio Makyu Co., Ltd., he has provided a wide range of internet-based business support, including website production, DTP design, SEO, listing ads, customer acquisition for stores, web media operations, and e-commerce site development.

Web production is not simply about creating a visually appealing website.
Who to communicate with, what to communicate, and in what order.
Where to build trust, and where to lead visitors to make an inquiry.
How information should be organized so that others can make decisions more easily.

This way of thinking also connects to his current medical and biotech businesses.

Medical research and Web3 projects tend to involve complex content. That is why organizing specialized content and making it available in a form that stakeholders can easily review is important.

Alongside web production, he has also been involved in software development and business system development.

At Studio Makyu Co., Ltd., web systems, business management systems, analysis tools, and Web3-related systems have been developed as systems needed for business operations.

For Fumihisa Kojima, system development is “not something intended to showcase technology itself,” but rather “a mechanism for moving business forward.”

Turning manual work into systems.
Converting complex information into databases.
Improving the efficiency of research and analysis.
Creating screens and management functions that make it easier for people to make decisions.

This experience later connected to compliance check systems, anti-social-force screening systems, bioinformatics support, and Web3-related systems.

One field he had been interested in since his student years was bioinformatics, life information science, and in silico analysis.

Bioinformatics is a field that analyzes life science data using information science methods. large volumes of information related to genes, proteins, cells, and diseases are organized and analyzed using computers.

Since the Studio Makyu Co., Ltd. period, support for joint research with Shiga University of Medical Science as part of this work, analysis tools such as BLAST, proprietary software, and large-scale computation using GPGPU have been part of his work.

The important point here is that Fumihisa Kojima has not been positioned as the central researcher of the papers, but rather has supported the computing environments, software, business structure, and funding needed to advance the research.

This field later led to the establishment of Biozipcode Inc., the cell-targeting technology Biozipcode™, and the commercialization of research related to diabetes and intractable diseases.

GPGPU is a technology that uses GPUs, originally designed for image processing, for scientific and large-scale computation.

Fumihisa Kojima became interested in the use of GPGPU in the field of bioinformatics and was involved in large-scale computation for research, analysis processing, and the development of computing environments.

This experience with GPGPU later expanded in two directions.

One was the medical, drug discovery, and bioinformatics fields through support for computational science.
The other was a crypto-asset mining business using GPUs.

At first glance, medical research and mining may appear to be entirely different fields. However, in the sense that both handle large amounts of computational resources, they share a common technical foundation.

Through this experience, Fumihisa Kojima came to understand technology as a business, including computing machines, electricity, cooling, equipment, operations, and profitability.

Around 2016, he became involved in supporting the development of crypto-asset mining farms at a relatively early stage in Japan.

mining equipment using GPUs and ASICs, power design, cooling, machine procurement, operations management, and profitability management were among the hands-on operational areas he experienced.

This experience led him to understand blockchain not merely as a buzzword, but as a business with real infrastructure, equipment, costs, risks, and revenue.

Later, he also became involved in crypto-asset issuance, wallets, transactions, blockchain system development, NFTs, and FinTech-related businesses.

The current Web3 projects related to GDT and Auring Ltd. are also based on the practical blockchain experience developed during this period.

In dealing with blockchain and crypto assets, unavoidable themes include AML, KYC, anti-social-force screening, and compliance.

At Japan Credit Information Service Co., Ltd., DMG Blockseer Japan Co., Ltd., and Senard Co., Ltd., he was involved in databases related to anti-social forces, compliance check services, abnormal transaction detection on blockchain, web crawling, and research systems using natural language processing.

What he learned in this field was “the newer the technology, the more important risk management becomes.”

In particular, Web3 and token-related businesses require careful attention to fund flows, identity verification, eligible sales jurisdictions, anti-social-force screening, anti-money-laundering measures, investor protection, terms of use, and risk disclosures.

In Fumihisa Kojima’s current Web3 projects, the focus cannot be limited to token issuance alone. KYC, AML, anti-social-force screening, and legal, tax, and accounting reviews must also be emphasized. This approach comes from his experience in AML and compliance.

The central business field today is Medical and Biotech.

At Biozipcode Inc., research and development related to diabetes, cancer, autoimmune diseases, and other intractable diseases; the cell-targeting technology Biozipcode™; data analysis; licensing business; and in silico research and development support are key areas of activity.

The origins of the company’s activities lie in joint research support with Shiga University of Medical Science dating back to the Studio Makyu Co., Ltd. period. In 2022, Biozipcode Inc. was established, and a joint research laboratory, the “Regenerative Medicine Development Course,” was established within Shiga University of Medical Science.

Subsequently, in 2026, the Department of Biocommunication Development, an industry-academia joint course at Kyoto University, Graduate School of Medicine and Faculty of Medicine, was established, developing the structure for research and development related to cell-targeted therapies, intractable diseases, diabetes, cancer, and related areas.

Fumihisa Kojima’s role is not to present himself as the researcher directly responsible for the research outcomes, but to support commercialization, fundraising, joint research structures, intellectual property, collaboration with pharmaceutical companies and medical institutions, and overseas expansion to continue and develop university-originated research.

In the medical field, many stages are required before research outcomes can reach society: preclinical research, clinical trials, safety evaluation, regulatory approval, manufacturing, sales, and collaboration with medical institutions. If any one of these is missing, social implementation cannot be achieved.

Fumihisa Kojima plays a business-side role in connecting these stages.

5-ALA is a theme related to diabetes and its complications, mitochondria, metabolism, and medical tourism concepts.

However, for 5-ALA, it is necessary to clearly distinguish among its treatment as a health food, as an active pharmaceutical ingredient, as part of clinical research, and for medical use.

Even when the same ingredient is involved, the country, intended use, labeling, sales format, and target users can significantly change the applicable regulations and the way it should be explained.

For this reason, this website also organizes information related to 5-ALA by separating research and development, products, clinical research, and medical services.

In the Web3 field, he is also involved in projects related to GDT, the Global Development Token.

GDT is positioned as a concept that combines diabetes research, medical tourism, 5-ALA-related products, biomarker testing, specialist consultations, and online medical consultations with Web3 mechanisms.

Auring Ltd. is an overseas entity positioned as the issuing entity for GDT. Fumihisa Kojima is involved as Representative Director / Director of the company, working on Web3 projects, token governance, overseas corporate operations, medical service payments, and the organization of KYC and AML frameworks.

In this field, his past experience in blockchain, AML, web marketing, medical research, and overseas expansion overlap. At the same time, because it involves medicine, investment, tokens, overseas entities, and medical tourism, information must be organized even more carefully than in ordinary business.

GDT and Auring Ltd. need to be reviewed by separating the following perspectives.

This website does not present GDT or Auring Ltd. in an overly promotional manner, but instead separates public information, roles, and points that should be reviewed.

Fumihisa Kojima’s current activities are not limited to Japan, but also include Palau, the UAE, the United States, and other regions.

In Palau, he is reviewing medical needs related to diabetes and its complications, the potential for clinical research, collaboration with medical institutions, and points of contact with government and related organizations while considering future medical expansion.

In the UAE, he is advancing initiatives involving medical tourism, clinic collaboration, discussions with investors and business partners, 5-ALA-related businesses, and connections with Web3 projects.

In overseas expansion, the points that must be reviewed differ by country, including medical systems, pharmaceutical regulations, tax, corporate law, crypto-asset regulations, medical advertising, and patient protection.

Therefore, in Fumihisa Kojima’s overseas business activities, collaboration with local medical institutions, specialists, and legal, tax, and financial professionals is important.